Research programme: type 1 diabetes mellitus - Semma Therapeutics

Drug Profile

Research programme: type 1 diabetes mellitus - Semma Therapeutics

Alternative Names: Stem cell-derived beta cells - Semma Therapeutics

Latest Information Update: 21 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Semma Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 24 Mar 2015 Semma Therapeutics enters into an undisclosed agreement with Novartis Pharmaceuticals
  • 24 Mar 2015 Semma Therapeutics in-licenses stem cell-derived beta cells technology from Harvard Stem Cell Institute for Type-1 diabetes mellitus
  • 09 Oct 2014 Preclinical trials in Type-1 diabetes mellitus in USA (unspecified route) (Semma Therapeutics website, April 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top